Tagged with B

Taiwan Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned provider to a healthcare partner. Wu goes on to offer her insights on the key market trends impacting the emerging field of precision medicine and shares her outlook on the…

Taiwan Today Su, CEO of Golden Biotechnology, introduces the innovative biotech developing a revolutionary botanical drug derived from the Taiwanese fungus Antrodia Camphorata. The company’s drug, Hocena®, has already received several orphan drug designations and thus far has exhibited promising results in key indications such as pancreatic cancer, non-small cell lung…

Spain Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand its reach across all forms of transport, offering logistics solutions rather than logistics products. Mr Rodríguez also lifts the lid on DB Schenker’s plans to grow its position in pharmaceutical logistics and…

Sweden Founded in Sweden in 2005, and with operations in 13 European countries, Bluefish Pharmaceuticals has become one of the world’s most progressive generic pharmaceuticals companies. CEO Berit Lindholm explains how Bluefish strives to compete on service rather than price by being a reliable partner to health authorities. She also emphasises…

China Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to develop highly differentiated therapies for infectious diseases with clear unmet medical needs, such as biofilm-associated medical device infections, H. pylori…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation.   19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…

Canada Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to driving change at a much larger level via a ‘collective impact’ approach.   When I encountered the concept of collective impact in the Stanford Social Innovation Review, I realized the possibilities lay…

Thailand Dr Tares Krassanairawiwong, secretary-general of the Thai FDA shares the recent reforms carried out in the hope of facilitating greater patient access to both domestic and internationally-produced treatments. Dr Krassanairawiwong also highlights the institution’s current priorities, including medical cannabis, positioning Thailand as a clinical trials hub, and further developing the…

Taiwan Scott Li, deputy director of H Spectrum, a biotech and talent incubator within the Foxconn group, explains the organization’s history and unique role in supporting Foxconn’s transition into healthcare. Li also shares his insights on the top challenges facing Taiwan’s innovation and entrepreneurial landscape.   H Spectrum is now positioned…

Opinion Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients.   Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of…

China Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over 100 companies, some of which have reconsidered listing on the Hong Kong Exchange, wary of the HKEX’s lukewarm performance.  …